Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

KLRS Relative to the S&P 500

Seasonal Chart Analysis

Analysis of the Kalaris Therapeutics Inc. (NASD:KLRS) seasonal charts above shows that a Buy Date of July 6 and a Sell Date of September 30 has resulted in a geometric average return of 17.6% above the benchmark rate of the S&P 500 Total Return Index over the past 4 years. This seasonal timeframe has shown positive results compared to the benchmark in 3 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 4 years by an average of 89.1% per year.

A word of caution: Only 4 years of data is available for shares of KLRS, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company is headquartered in Berkeley Heights, NJ.

To download KLRS seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: KLRS